DURECT (DRRX) Stock Price, News & Analysis

Company Overview

DURECT Corporation (NASDAQ: DRRX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, small-molecule therapeutics in areas of high unmet medical need. Founded in 1998 and headquartered in California, DURECT pursues programs in inflammatory, fibrotic, and central nervous system disorders. The company’s research is supported by a proprietary drug delivery platform designed to optimize the release profiles and bioavailability of its drug candidates.

The company’s leading clinical asset, DUR-928, is an endogenous regulator being evaluated for the treatment of liver diseases, kidney disorders, and acute organ injury. Another key program, POSIMIR, is an investigational, long-acting local analgesic formulation intended to manage postsurgical pain. DURECT also maintains a robust preclinical pipeline that leverages its small-molecule chemistry expertise to target novel pathways in autoimmune conditions and oncology.

Beyond its internal pipeline, DURECT commercializes RELiZORB®, an immobilized lipase cartridge designed to improve fat absorption in patients receiving enteral nutrition, and it has partnered with pharmaceutical companies to license its drug delivery technologies. The IntraPhase™ controlled-release platform is used to develop injectable depot formulations, while its ALZET® osmotic pumps are utilized by researchers worldwide for sustained compound delivery in preclinical studies.

Under the leadership of President and CEO Andrew B. Allen, DURECT collaborates with academic institutions, biotechnology firms, and pharmaceutical partners to advance both its therapeutic candidates and delivery systems. The company’s global reach extends through strategic alliances and licensing agreements aimed at accelerating clinical development and expanding access to its proprietary technologies.

Key Stats

• Today's Range: $1.91 to $1.91
• 50-Day Range: $0.52 to $1.96
• 52-Week Range: $0.48 to $2.64
• Volume: N/A
• Average Volume: 699,433 shs
• Market Capitalization: $59.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

DURECT Stock Analysis - MarketRank™

DURECT scored higher than 33% of companies evaluated by MarketBeat, and ranked 766th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for DURECT.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for DURECT are expected to decrease in the coming year, from ($0.50) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DURECT is -19.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DURECT is -19.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DURECT has a P/B Ratio of 6.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.27% of the float of DURECT has been sold short.

Short Interest Ratio / Days to Cover

DURECT has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DURECT has recently decreased by 19.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DURECT does not currently pay a dividend.

Dividend Growth

DURECT does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.19

Percentage of Shares Shorted

1.27% of the float of DURECT has been sold short.

Short Interest Ratio / Days to Cover

DURECT has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DURECT has recently decreased by 19.51%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

DURECT has a news sentiment score of 1.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for DURECT this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added DURECT to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DURECT insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of DURECT is held by insiders.

Percentage Held by Institutions

Only 28.03% of the stock of DURECT is held by institutions.

DRRX Stock Analysis - Frequently Asked Questions

How have DRRX shares performed this year?

DURECT's stock was trading at $0.75 on January 1st, 2025. Since then, DRRX stock has increased by 154.7% and is now trading at $1.91.

How were DURECT's earnings last quarter?

DURECT Corporation (NASDAQ:DRRX) announced its quarterly earnings data on Tuesday, August, 12th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The specialty pharmaceutical company had revenue of $0.45 million for the quarter, compared to analysts' expectations of $0.32 million. DURECT had a negative net margin of 96.19% and a negative trailing twelve-month return on equity of 259.16%.

When did DURECT's stock split?

DURECT shares reverse split on the morning of Tuesday, December 6th 2022.The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are DURECT's major shareholders?

DURECT's top institutional shareholders include Richmond Brothers Inc. (4.68%), Ingalls & Snyder LLC (4.35%), Dalton Investments Inc. (2.40%) and Beirne Wealth Consulting Services LLC (1.01%).
View institutional ownership trends.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include CymaBay Therapeutics (CBAY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), GE Aerospace (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/21/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRRX
• CIK: 1082038
• Web: www.durect.com
• Phone: (408) 777-1417
• Fax: 408-777-3577
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.32 million
• Net Margins: -96.19%
• Pretax Margin: -416.01%
• Return on Equity: -259.16%
• Return on Assets: -71.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.98
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $1.66 million
• Price / Sales: 35.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 6.59

Miscellaneous

• Outstanding Shares: 31,054,000
• Free Float: 30,060,000
• Market Cap: $59.31 million
• Optionable: Optionable
• Beta: 0.92